Diagnostic test | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
---|---|---|---|---|
Pre-treatment | ||||
General population (i) Using Kato Katz technique as gold standard | ||||
POC-CCA | 96.3% (95%CI:93.1–98.3) | 25.4% (95%CI: 19.2–32.5) | 63.8% (95%CI: 58.7–68.8) | 83.3% (95%CI: 70.7–92.1) |
(ii) Using combined gold standarda | ||||
POC-CCA | 97.6% (95%CI:95.5–98.9) | 100 (95%CI:92.1–100) | 100 (95%CI:99–100) | 83.3% (95%CI:70.7–92.1) |
In the HIV-1 seropositive group (i) Using Kato Katz technique as a gold standard | ||||
POC-CCA | 93.3% (95%CI:68.1–99.8) | 28.6% (95%CI:8.4–58.1) | 58.8% (95%CI:36.6–77.9) | 80% (95%CI:28.4–99.5) |
(ii) Using combined gold standarda | ||||
POC-CCA | 96% (95%CI:79.6–99.9) | 100% (95%CI:39.8–100) | 100% (95%CI:85.8–100) | 80% (95%CI:28.4–99.5) |
Four weeks after praziquantel treatment | ||||
In general population (i) Using Kato Katz technique as gold standard | ||||
POC-CCA | 47.8% (95%CI: 26.8–69.4) | 74.7% (95%CI: 67.9–80.8) | 19% (95%CI: 9.9–31.4) | 92.1% (95%CI: 86.5–95.8) |
(ii) Using combined gold standarda | ||||
POC-CCA | 84.4% (95%CI:74.4–91.7) | 100% (95%CI:97.4–100) | 100% (95%CI:94.5–100) | 92.1% (95%CI:86.5–95.8) |
In the HIV-1 seropositive group | ||||
(i) Using Kato Katz technique as gold standard | ||||
POC-CCA | 100% (95%CI:2.5–100) | 63.6% (95%CI:30.8–89.1) | 20% (95%CI:0.5–71.6) | 100% (95%CI:59–100) |